BioPharmaTrend.com is a leading blog covering the pharmaceutical sector with a focus on Artificial Intelligence, Drug Discovery, and the ways that the healthcare sector is changing due to the digital transformation happening within the industry. Having also built an analytics platform for the sector, BioPharmaTrend understands the impact of technology not only from a journalistic standpoint, but from the viewpoint of a tech innovator who has created their own platform. POLARISqb was cited in their recent article, “Pharmaceutical Artificial Intelligence in 2020: The Sector is Heating Up For Investments,” alongside leading companies like Xtalpi, Insitro, ImmunAI, Transilico, and others.
In reading the fundraising numbers cited in the article, it is clear that the AI sector truly is heating up in terms of investments. Xtalpi certainly leads the way, having secured $319 million in capital, but other companies have had Series B rounds ranging from $20 million to $150 million in 2020. As we continue to see artificial intelligence become more commercially viable and stable technologies within the sector, the speed with which pharmaceutical achievements are accomplished will become greater, lowering costs and providing access to medical breakthroughs to many patients who may have previously not had treatment options previously. Also, developments within the quantum computing sector are advancing at a meteoric pace, and with these developments come opportunities to apply more advanced computing techniques, as we do in POLARISqb, to help develop novel treatments for diseases that have previously proven difficult to treat or cure. This is one way that we are unique among the companies named in the article, as we were the only company recognized that is utilizing a proven quantum solution within the biopharma sector.
It is for precisely this kind of work that BioPharmaTrend has recognized POLARISqb, as our use of quantum computing to power optimization and annealing processes within drug discovery holds the promise of revolutionizing the timelines for developments of new drugs and treatments. In the article, they identify our, “new drug discovery platform, which combines quantum-inspired technology, machine learning, hybrid quantum mechanics, and molecular mechanics simulations,” as a promising development for cutting drug development timelines by up to 90%. The applicability of the POLARISqb system continues to grow, we work to ensure our software stack is agnostic in most respects, meaning that the algorithms can be used on a variety of compute architectures. We are honored to be recognized alongside industry leaders and other startups that are among the vanguard of the use of artificial intelligence in the pharmaceutical sector, and look forward to a future where our technology is able to change the world, providing drug treatments to cure all diseases for all people.
